Mercato chiuso -
Altri mercati azionari
|
Variaz. 5gg | Var. 1 gen. | ||
49,13 USD | -0,47% | +6,11% | -1,21% |
Attività
- prodotti farmaceutici (70,6%): farmaci da prescrizione nelle aree della medicina specialistica (59,3% delle vendite nette; per il trattamento della sclerosi multipla, delle malattie neurologiche, delle malattie infiammatorie, delle malattie autoimmuni, delle malattie rare, dei tumori e delle malattie ematologiche rare) e della medicina generale (40,7%; principalmente per il trattamento del diabete e delle malattie cardiovascolari);
- vaccini umani (17,4%): vaccini pediatrici, vaccini per l'influenza, la meningite e la poliomielite, vaccini di richiamo e vaccini per i viaggiatori e le aree endemiche;
- prodotti sanitari di consumo (12%).
Alla fine del 2023, il Gruppo aveva 54 siti di produzione in tutto il mondo.
Le vendite nette sono distribuite geograficamente come segue: Francia (5,5%), Europa (18,6%), Stati Uniti (43%), Nord America (1,6%) e altro (31,3%).
Numero di dipendenti: 86 088
Vendite per attività
EUR in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Biopharma
88,0
%
| 30 688 | 71,4 % | 37 890 | 88,0 % | +23,47% |
Consumer Healthcare
12,0
%
| 5 080 | 11,8 % | 5 180 | 12,0 % | +1,97% |
Vendite per regione
EUR in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States
43,0
%
| 18 275 | 42,5 % | 18 512 | 43,0 % | +1,30% |
Rest of the World
26,1
%
| 8 386 | 19,5 % | 11 254 | 26,1 % | +34,20% |
Europe
18,6
%
| 7 703 | 17,9 % | 8 013 | 18,6 % | +4,02% |
China
6,8
%
| 3 123 | 7,3 % | 2 912 | 6,8 % | -6,76% |
France
5,5
%
| 2 296 | 5,3 % | 2 379 | 5,5 % | +3,61% |
Dirigenti
Dirigenti | Titolo | Età | Da |
---|---|---|---|
Paul Hudson
CEO | Chief Executive Officer | 56 | 01/09/19 |
Madeleine Roach
COO | Chief Operating Officer | 39 | 01/01/22 |
Chief Tech/Sci/R&D Officer | 51 | - | |
Nestle Frank
CTO | Chief Tech/Sci/R&D Officer | - | 01/09/16 |
Houman Ashrafian
CTO | Chief Tech/Sci/R&D Officer | 49 | 11/09/23 |
Dietmar Berger
CTO | Chief Tech/Sci/R&D Officer | - | 01/01/19 |
Arnaud Delépine
IRO | Public Communications Contact | - | - |
Raj Verma
PRN | Corporate Officer/Principal | - | 01/12/20 |
- | - | ||
Corporate Officer/Principal | 62 | 01/01/15 |
Amministratori
Amministratori | Titolo | Età | Da |
---|---|---|---|
Patrick Kron
BRD | Director/Board Member | 70 | 01/05/14 |
Lise Kingo
BRD | Director/Board Member | 62 | 28/04/20 |
Gilles Schnepp
BRD | Director/Board Member | 64 | 22/05/20 |
Frédéric Oudéa
CHM | Chairman | 60 | 02/09/22 |
Rachel Duan
BRD | Director/Board Member | 52 | 28/04/20 |
Antoine Yver
BRD | Director/Board Member | 66 | 03/05/22 |
Carole Ferrand
BRD | Director/Board Member | 53 | 03/05/22 |
Paul Hudson
CEO | Chief Executive Officer | 56 | 01/09/19 |
Director/Board Member | 58 | 30/04/19 | |
Emile Voest
BRD | Director/Board Member | 64 | 03/05/22 |
Classe di azioni
Voto | Quantità | Flottante | Autocontrollo | Flottante totale | |
---|---|---|---|---|---|
Azione A | 1 | 1 264 799 969 | 1 100 464 483 ( 87,01 %) | 13 450 388 ( 1,063 %) | 87,01 % |
Partecipazioni
Nome | Azioni | % | Valorizzazione |
---|---|---|---|
SANOFI 1.28% | 16 245 648 | 1.28% | 1 595 920 473 $ |
SANOFI INDIA LIMITED 60.40% | 13 909 587 | 60.40% | 1 353 934 300 $ |
EUROAPI 29.77% | 28 298 074 | 29.77% | 85 420 566 $ |
MEIRAGTX HOLDINGS PLC 7.39% | 4 697 737 | 7.39% | 28 515 264 $ |
LAVA THERAPEUTICS N.V. 7.30% | 1 919 455 | 7.30% | 6 391 785 $ |
ENENTO GROUP OYJ 0.12% | 29 249 | 0.12% | 545 225 $ |
Coordinate società
Società del gruppo
Nome | Categoria e settore |
---|---|
Chattem, Inc.
Chattem, Inc. Pharmaceuticals: MajorHealth Technology Chattem, Inc. engages in the manufacture of over-the-counter health and beauty care products. It makes anti-dandruff shampoos, medicated skin care, topical pain care, oral care and internal over-the-counter products. The firm distributes its products to mass merchandisers, drugstores and food retail channels. The company was founded by Zeboim Cartter Patten on February 21, 1879 and is headquartered in Bridgewater, NJ. |
Pharmaceuticals: Major
|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. |
Medical Specialties
|
Bioverativ Therapeutics, Inc.
Bioverativ Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bioverativ Therapeutics, Inc. develops pharmaceutical products. It develops medicines for chronic diseases such as hemophilia, anemia, multiple sclerosis, and autoimmune disorders. The company is headquartered in Cambridge, MA. |
Pharmaceuticals: Major
|
Aventis, Inc.
| |
Sanofi-Synthélabo Ltd.
Sanofi-Synthélabo Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Sanofi-Synthélabo Ltd. is a pharmaceutical company based in Reading, UK. The British company was founded in 1990 and specializes in manufacturing and distributing solid-dose and pharmaceutical products. |
Pharmaceuticals: Major
|
Sanofi Pasteur, Inc.
Sanofi Pasteur, Inc. Pharmaceuticals: MajorHealth Technology Sanofi Pasteur, Inc. provides vaccines for the prevention and treatment of diseases. It develops and manufactures influenza vaccine against the pandemic influenza virus. The company was founded in 1897 and is headquartered in Swiftwater, PA. |
Pharmaceuticals: Major
|
Sanofi-aventis Ireland Ltd.
Sanofi-aventis Ireland Ltd. Pharmaceuticals: MajorHealth Technology Sanofi-aventis Ireland Ltd. manufactures pharmaceutical products for cardiovascular, central nervous system, metabolic disorders, cardiometabolic, oncology, thrombosis, and vaccines. The company is headquartered in Dublin, Ireland. |
Pharmaceuticals: Major
|
Sanofi-Aventis Europe SAS
Sanofi-Aventis Europe SAS Pharmaceuticals: MajorHealth Technology Part of Sanofi, Sanofi-Aventis Europe SAS is a pharmaceutical company based in Paris, France. The French company manufactures pharmaceuticals. The CEO of the private company is Jérôme Contamine. |
Pharmaceuticals: Major
|
Genzyme Therapeutic Products LP
Genzyme Therapeutic Products LP BiotechnologyHealth Technology Part of Sanofi, Genzyme Therapeutic Products LP is a private company that specializes in biological products except diagnostic substances. The company is based in Boston, MA. |
Biotechnology
|
Settore
Vendite per attività
Vendite per regione
Revisioni EPS
Variaz. 1 gen. | Capi. | |
---|---|---|
+25,83% | 661 Mrd | |
+27,00% | 566 Mrd | |
-6,76% | 352 Mrd | |
+20,34% | 332 Mrd | |
+3,00% | 283 Mrd | |
+13,09% | 231 Mrd | |
+5,46% | 200 Mrd | |
-9,61% | 195 Mrd | |
-6,26% | 145 Mrd |
- Borsa valori
- Azioni
- Azione SAN
- Azione SNY
- Società Sanofi